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Abstract. The study aimed to further characterise HLA encoded risk factors of type 1 diabetes (T1D) in Brazilian population and
test the capability of a low resolution full-house DR-DQ typing method to find subjects at diabetes risk. Insulin and CTLA-4 gene
polymorphisms were also analysed. The method is based on an initial DQB1 typing supplemented by DQA1 and DR4 subtyping
when informative. Increased frequencies of both (DR3)-DQA1*05-DQB1*02 and DRB1*04-DQA1*03-DQB1*0302 haplotypes
were detected among patients. DRB1*0401, *0402, *0404 and *0405 alleles were all common in DQB1*0302 haplotypes
and associated with T1D. (DRB1*11/12/1303)-DQA1*05-DQB1*0301, (DRB1*01/10)-DQB1*0501, (DRB1*15)-DQB1*0602
and (DRB1*1301)-*0603 haplotypes were significantly decreased among patients. Genotypes with two risk haplotypes or a
combination of a susceptibility associated and a neutral haplotype were found in 78 of 126 (61.9%) T1D patients compared to
8 of 75 (10.7%) control subjects (P < 0.0001). Insulin gene −2221 C/T polymorphism was also associated with diabetes risk:
CC genotype was found among 83.1% of patients compared to 69.3% of healthy controls (P = 0.0369, OR 1.98) but CTLA-4
gene +49 A/G polymorphism did not significantly differ between patients and controls. Despite the diversity of the Brazilian
population the screening sensitivity and specificity of the used method for T1D risk was similar to that obtained in Europe.
1. Introduction
Type 1 diabetes is a result of immune mediated de-
struction of insulin producing beta-cells in pancreatic
islets. The central role of HLA region or human MHC
associated genetic susceptibility has been known for
thirty years and polymorphisms of class II region en-
coded molecules, especially DQ molecules, seem to be
the single most important genetic disease risk determi-
nant. In addition several loci in other chromosomes
are contributing to the genetic risk, but only the ef-
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fects of insulin and perhaps CTLA-4 gene region poly-
morphisms can be considered as firmly established [1].
DQ molecules associated with different strength with
both disease risk and protection against it can be dis-
cerned, and interaction of the molecules encoded by
the genotype is important as demonstrated by a clear
dominant effect of strong protective molecules. In ad-
dition to HLA-DQ molecules there are other loci within
HLA region affecting disease susceptibility. The role of
DR molecules on DQ mediated susceptibility has been
clearly demonstrated in DQA1*03-DQB1*0302 posi-
tive DR4 haplotypes where some particular DR4 sub-
type encoding alleles are associated with disease risk
and others are abolishing the DQA1*03-DQB1*0302
associated susceptibility. There is also evidence for the
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role of class I alleles or loci in close vicinity in certain
haplotypes as well as multiple other loci like DP, TNF
region and a locus telomeric to HLA close to D6S2223
microsatellite marker [2–6].
MHC is the most polymorphic mammalian gene re-
gion and gene density there is extremely high. Com-
plete high-resolution typing for HLA region is practi-
cally impossible, although much effort is made in tis-
sue transplantation for exact matching of the donor re-
cipient pairs for all molecules important in possible
induction of immunological rejection.
Estimation of HLA related genetic risk for type 1
diabetes is at the moment used for selection of subjects
for clinical prevention studies and studies aiming to
identify environmental factors contributing to the beta-
cell damaging autoimmune process [7,8], but in future
the identification of individuals at risk might be part of
clinical routine if preventive measures will be devel-
oped. Study subjects in these projects have been either
selected among first degree relatives or among general
population. In the latter case the need for a simple and
inexpensive screening protocol is accentuated as great
number of samples must be processed. In addition to
the huge polymorphism of HLA gene region it is also
characterised by strong linkage disequilibrium, which
makes testing for disease risk associated determinants
more simple. Recombinations between DRB1, DQA1
and DQB1 genes are extremely rare and alleles in these
loci are found in fixed combinations. Variability in
major allele combinations still exists between various
populations due to some ancient recombinatory events.
Definition of either DRB1 or DQB1 alleles is in sev-
eral haplotypes thus enough for low resolution typing,
whereas in other cases more diverse combinations ex-
ist. For purposes of diabetes screening an emphasis
can be put on polymorphisms known to be relevant for
disease susceptibility.
We have developed a semiautomated sequence spe-
cific oligonucleotide hybridisation method for diabetes
screening based on microtitre plate format and time-
resolved fluorometry reading of hybridisation reactions
of lanthanide chelate labelled oligonucleotides. PCR
amplification of gene regions of interest directly from
punched pieces of dried blood spots makes DNA ex-
traction unnecessary and use of various lanthanide la-
bels allows simultaneous measurement of three differ-
ent signals in each microtitre plate well. The method
was originally developed for testing the presence of
T1D associated DQB1*02 and DQB1*0302 as well as
protective DQB1*0301 and DQB1*0602/3 alleles [9]
and was used in the Finnish Diabetes Prediction and
Prevention (DIPP) study [7]. It has later on been ap-
plied also for typing DQA1 alleles informative for dia-
betes risk when used in combination with DQB1 data
and also for relevant DR4 subtypes [10]. These addi-
tional steps have been shown to increase the sensitiv-
ity and specificity of risk estimation considerably es-
pecially in more diverse Greek and Hungarian popu-
lations, whereas the effect in the less diverse Finnish
populations was only modest [11]. Addition of a series
of new DQB1 probes made possible a low-resolution
full-house genotyping of all common Caucasian hap-
lotypes [12,13]. An assay based on similar technology
has also been developed for typing of insulin gene and
CTLA-4 polymorphisms [14]. In the present study we
aimed to investigate the capability of the methodology
in estimation of T1D risk in one of the most diverse
human populations, that in Brazil.
2. Subjects and methods
There were 126 patients diagnosed with type 1 di-
abetes, 72 males and 54 females. They were recruit-
ed in the out-patient Diabetes Center of UNIFESP-S?o
Paulo, characterized by the presence of early-onset ke-
tosis prone diabetes and insulin dependence directly
after diagnosis. As controls, we studied a group of 75
unrelated non diabetic subjects without family history
of diabetes recruited from the same area. Mean age at
onset in patients was 11.7 (SD 4.7) years. 86 of the pa-
tients were white, 17 black, 19 mulatto, 3 oriental and
one of unknown racial group. As controls, we studied
a group of 75 unrelated non diabetic subjects without
family history of diabetes recruited from the same area
and with a similar racial distribution.
HLA genotyping was made by panels of sequence
specific oligonucleotide probes hybridised with ampli-
fied polymorphic regions of DQB1, DQA1 and DRB1
genes. One of the primers was biotinylated and ampli-
cons were transferred and fixed on streptavidin coat-
ed microtitre plate wells where they were denatured
and hybridised with oligonucleotides. Twelve DQB1
probes, 3 DQA1 probes and 6 DRB1 probes were used
in mixes of three probes labelled with various lan-
thanide (Europium, Samarium and Terbium) chelates.
Specific signals for each label were measured after
washes and addition of enhancement solution by time-
resolved fluorometry. Details of the method including
primer and probe sequences have been described ear-
lier [9,10,12]. Similar method was used for genotyp-
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ing of insulin gene −2221 C/T and CTLA-4 +49 A/G
polymorphisms [14].
Differences in haplotype and genotype frequencies
between patients and controls were compared using
Chi-square test with Yates’ correction and odds ratios
(OR) calculated according to the formula: a/b × d/c in
which a and c are the numbers of marker positive pa-
tients and control subjects, and b and d are the numbers
of marker negative patients and control subjects. Pos-
itive predictive value (PPV) was calculated according
to formula:
sensitivity× prevalence / sensitivity× prevalence
+ (1 − specificity) × (1 − prevalence)
and negative predicive value according to formula:
specificity × (1 − prevalence) / (1 − sensitivity)
× prevalence+ specificty × (1 − prevalence)
3. Results
All samples were analysed for the presence of
DQB1, DQA1 and DR4 alleles detectable with the used
oligonucleotide panels. Haplotypes of alleles in dif-
ferent loci were deduced based on the known existing
allelic associations. Table 1 lists separately haplotypes
detected at least twice among either T1D patients or
control subjects. DQA1 and DR4 subtyping reagents
were designed for the specific purpose of detecting alle-
les known to characterise haplotypes differentially as-
sociated with diabetes risk and thus the level of reso-
lution was variable between haplotypes. Allele defini-
tions based on deduction are expressed within paren-
theses in the following text.
HLA-(DRB1*03)-DQA1*05-DQB1*02 and DRB1*
04-DQA1*03-DQB1*0302 haplotypes were highly
significantly increased among T1D patients. HLA-
(DRB1*03)-DQA1*05-DQB1*02 haplotype was
found in 60% of patients reflecting its high frequen-
cy also in background population. The frequency of
DRB1*04-DQB1*0302 haplotypes was 12% among
controls, but nearly half of patients still were posi-
tive. Odds ratio for DRB1*04-DQB1*0302 haplotypes
was slightly higher than that of (DRB1*03)-DQA1*05-
DQB1*02. All major DRB1*04 subtypes usually
associated with diabetes susceptibility, DRB1*0401,
*0402, *0404 and *0405 were increased and common
among T1D patients, DRB1*0403/6 known to be pro-
tective was not found among patients, but was also
present in only two healthy controls and the difference
was thus not significant.
(DRB1*01/10)-DQB1*0501, (DRB1*11/*12/*130
3)-DQA1*05-DQB1*0301and (DRB1*15)-DQB1*06
02 were the most common haplotypes found in
background population and they were all significant-
ly decreased among T1D cases. (DRB1*1301)-
DQB1*0603 was also significantly decreased.
When the genotypes among T1D patients and con-
trols were compared, the number of samples with each
individual genotype became small due to the limited
number of studied samples. (DRB1*03)-DQA1*05-
DQB1*02/DRB1*0401/2/4/5-DQA1*03-DQB1*0302
genotype was, however, associated with a very strong
disease risk, 26.2% of patients were positive com-
pared to none of the studied controls with this geno-
type (OR 54.1, P < 0.0001). Homozygosity for HLA-
(DRB1*03)-DQA1*05-DQB1*02 haplotype was al-
so significantly increased, 9.5% among patients com-
pared to 1.3% of controls (P = 0.0468, OR 5.42).
(DRB1*03)-DQA1*05DQB1*02/ (DR11/12/1303)-D
QA1*05-DQB1*0301 genotype was the only indi-
vidual genotype, which was significantly decreased
among patients (0% vs. 6.7%, P = 0.0135). When
genotypes formed by five most common haplotypes
were analysed for Hardy-Weinberg equilibrium among
T1D cases the distribution differed significantly from
the expected (Chi square 34.037, df = 14, P <
0.005). Combination of two different HLA risk hap-
lotypes, (DRB1*03)-DQA1*05-DQB1*02/DRB1*04-
DQA1*03-DQB1*0302, was more common than ex-
pected (Obs. 34, Exp. 22.3, Chi-square 6.074) and ho-
mozygosity for DRB1*04-DQB1*0302 less common
than expected (Obs. 2, Exp. 8.1, Chi-square 4.619).
Genotypes produced by the five most common hap-
lotypes within control group were instead in Hardy-
Weinberg equilibrium (Chi square 17.563, df = 14,
n.s.).
For further analysis of genotype effect we classi-
fied the haplotypes to susceptibility associated, neu-
tral and protective. This classification was based
on earlier literature [13,15–18] and on the findings
of this study. HLA-(DRB1*03)-DQA1*05-DQB1*02
and DRB1*0401/2/4/5-DQA1*03-DQB1*0302 haplo-
types together with DRB1*0405-DQA1*03-DQB1*02
were thus classified as susceptibility haplotypes (S),
all haplotypes found significantly decreased in this
study (Table 1) as well as (DRB1*07)-DQA1*0201-
DQB1*0303, (DRB1*14)-DQB1*0503,and DRB1*04
03-DQA1*03-DQB1*0302 were classified as protec-
tive. These three last mentioned haplotypes were rare
among the studied population and significant differ-
ences were not seen. The results of this risk classifica-
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Table 1
Frequency of subjects positive for defined HLA-DR-DQ haplotypes among diabetic patients and
healthy controls
DR-DQ haplotype T1D Controls OR P
N % N %
(DRB1*01/10)-DQB1*0501 20 15.9 26 34.7 0.36 0.0038
(DRB1*15)-DQB1*0601 0 0.0 3 4.0
(DRB1*15)-DQB1*0602 6 4.8 15 20.0 0.20 0.0015
(DRB1*16)-DQB1*0502 9 7.1 3 4.0
(DRB1*03)-DQA1*05-DQB1*02 76 60.3 15 20.0 6.08 < 0.0001
DRB1*0401-DQA1*03-DQB1*0301 1 0.8 1 1.3
All DRB1*04-DQA1*03-DQB1*0302 62 49.2 9 12.0 7.10 < 0.0001
DRB1*0401 14 11.1 1 1.3 9.25 0.0229
DRB1*0402 18 14.3 3 4.0 4.00 0.0386
DRB1*0403/6 0 0.0 2 2.7
DRB1*0404 8 6.3 0 0.0
DRB1*0405 21 16.7 3 4.0 4.80 0.0141
DRB1*0405-DQB1*03-DQB1*02 2 1.6 0 0.0
(DRB1*11/12/1303)-DQA1*05-DQB1*0301 12 9.5 20 26.7 0.29 0.0026
(DRB1*07)-DQA1*0201-DQB1*02 13 10.3 12 16.0
(DRB1*1301)-DQB1*0603 3 2.4 8 10.7 0.20 0.0293
(DRB1*1302)-DQB1*0604 8 6.3 3 4.0
(DRB1*14)-DQB1*0503 3 2.4 3 4.0
(DRB1*07)-DQA1*0201-DQB1*0303 1 0.8 4 5.3
(DRB1*07/9)-DQA1*03-DQB1*02 5 4.0 2 2.7
(DRB1*08)-DQB1*0301 3 2.4 3 4.0
(DRB1*08)-DQB1*04 6 4.8 6 8.0
(DR9)-DQA1*03-DQ303 1 0.8 2 2.7
Total 126 75
tion are shown in Table 2. Distribution of genotypes is
clearly different between groups and one can see a risk
gradient dependent on the haplotypic combination. A
very high risk is associated with the presence of two
risk haplotypes.Positive predictive value (PPV) for this
genotype is 3.4% based on prevalence of 0.12% of T1D
in Brazilian population of 15 years children. This is cal-
culated from the yearly incidence of 8.0/100,000 chil-
dren reported from Sao Paulo [19]. The presence of on-
ly one risk haplotype is associated with much lesser risk
and this is further reduced by the simultaneous pres-
ence of a protective haplotype. 61.9% of T1D patients
were found to belong to the two highest risk genotypes
compared to only 10.7% of background population and
PPV for this genotype group would be 0.69% and nega-
tive predictive value (NPV) 99.95%. At least one of the
haplotypes associated with disease susceptibility was
found among 84.9% of diabetes patients compared to
29.3% of controls (PPV 0.34%, NPV 99.97%).
Polymorphisms of insulin gene region and CTLA-4
gene were analysed using −2221 C/T and +23 A/G
polymorphisms shown to be in association with disease
risk in several populations. Tables 3 and 4 summarise
the results. Insulin gene −2221 CC genotype was sig-
nificantly increased among T1D patients, but no sig-
nificant differences were found in CTLA-4 genotypes
(Table 4). No significant differences were seen in the
frequency of these markers between patients divided
to high and low risk genotypes (S/S and S/N vs oth-
ers, data not shown). Distribution of INS and CTLA-4
genotypes were in Hardy-Weinberg equilibrium in both
groups.
4. Discussion
Brazilian population with its mixed ancestry is an es-
pecially diverse one and thus able to give some special
insights to research of diseases with a genetic compo-
nent. Variability of allelic associations makes genetic
disease risk studies also demanding as markers used be-
cause of their linkage to disease risk genes themselves
may not necessarily be useful to the extent found in
more homogeneous populations.
In the present study we could detect as expected the
strong association of the two major diabetes risk haplo-
types, DRB1*03-DQB1*05-DQB1*02 and DRB1*04-
DQA1*03-DQB1*0302 with the disease. DR3 and
DR4 associations were detected already in serologi-
cal studies in Brazilian population [20] and confirmed
later on by sequence based typing [21,22]. Similar-
ly the protective effect of DR15(2) and respectively,
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Table 2
Frequency of genotypes consisting of susceptibility associated (S),
neutral (N) and protective (P) haplotypes among patients with type
1 diabetes and control subjects. Positive predictive value (PPV) and
negative predictive value (NPV) were calculated based on a preva-
lence of 0.12%
Genotype T1D Controls O.R. PPV NPV
N % N %
S/S 49 38.9 1 1.3 47.09 3.39 99.93
S/N 29 23.0 7 9.3 2.90 0.30 99.90
S/P 27 21.4 14 18.7 1.19 0.14 99.88
N/N 6 4.8 7 9.3 0.49 0.06 99.87
P/N 9 7.1 21 28.0 0.20 0.03 99.85
P/P 6 4.8 25 33.3 0.10 0.02 99.83
Total 126 75
P < 0.0001, df = 5.
DRB1*1501-DQB1*0602, was detected in all these
earlier studies.
The study based on 56 families with a diabet-
ic child by Volpini and colleagues confirmed the
risk conferred by DRB1*03-DQA1*05-DQB1*02 and
DRB1*04-DQA1*03-DQB1*0302 haplotypes, but the
role of DRB1*0401 subtype among the transmitted
DR4 haplotypes was prominent [21]. We could in-
stead detect the association of all other common DR4
subtypes than DRB1*0403/6 with disease suscepti-
bility. The increase of DRB1*0404 allele was on-
ly of borderline significance, but it was not at all de-
tected among healthy controls. The numbers do not
really allow a more thorough estimation of relative
strength of disease risk between various DRB1*04 alle-
les, but suggest strong association with each one except
DRB1*0403/06. This allele was rare also among con-
trol population although its lack among diabetic cases
is in line with protective effect confirmed in numer-
ous studies [23]. Findings reported by Fernandes and
coworkers support our results although findings for no
DR4 subtypes were significant due to the small num-
bers in the patient series of 64 cases [22].
Volpini et al. suggested that the lack of the protective
effect of DRB1*15-DQA1*0102-DQB1*0602 would
be a peculiar characteristic of Brazilian population [21].
This was probably a chance effect in a small sample
series as we found this haplotype in fact to have the
strongest protective effect. Similarly did Fernandes
and coworkers find a significant decrease of DRB1*15
and DQB1*0602/03 alleles [22].
The protection conferred by DRB1*13-DQB1*0301
and DRB1*11-DQB1*0301found by Volpini et al. [21]
was confirmed in our series although both haplotypes
were detected as a group together with all DQA1*05-
DQB1*0301 positive haplotypes. DRB1*01-DQB1*
0501 haplotype was also protective in both studies.
Table 3
Genotypes of Insulin gene −2221 C/T polymorphism among T1D
patients and controls
Genotype T1D Controls OR P
N % N %
CC 103 83.1 52 69.3 1.98 0.0369
CT 19 15.3 19 25.3
TT 2 1.6 4 5.3
Total 124 75
Table 4
Genotypes of CTLA-4 gene+49 A/G polymorphism
among T1D patients and controls
Genotype T1D Controls
N % N %
AA 42 33.9 30 40.0
AG 63 50.8 34 45.3
GG 19 15.3 11 14.7
Total 124 75
This haplotype was also the most common in back-
ground population and thus most affected by secondary
decrease due to the increase of some haplotypes. In
the present study we could also detect a significant-
ly decreased frequency of (DRB1*1301)-DQB1*0603
haplotype. (DRB1*07)-DQA1*0201-DQB1*02 and
(DR8)-DQB1*04 haplotypes were neutral like also
DQA1*03-DQB1*02 haplotype apparently associated
with DRB1*07 and/or DRB1*09 alleles as found in
black Brazilian population [24]. Samples with this
haplotype without DRB1*0405 were always found in
black or mulatto patients.
(DRB1*07)-DQA1*0201-DQB1*0303 and (DRB1
*14)-DQB1*0503 haplotypes have been found strong-
ly protective in several populations [13,16,25–28], but
they were not found significantly decreased among T1D
patients in this study. However, these were relative-
ly rare also in the background population and a ten-
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dency to decreased frequency was found especially for
(DRB1*07)-DQA1*0201-DQB1*0303 haplotype.
Classification of haplotypes to risk and protec-
tion associated or neutral ones allowed a simple
risk grading system based on six possible genotyp-
ic combinations of haplotypes. Genotypes with two
diabetes risk associated haplotypes are in fact all
but one (DRB1*03)-DQA1*05-DQB1*02/DRB1*04-
DQB1*03-DQB1*0302 heterozygous demonstrating
again the well known high risk associated with this par-
ticular genotype. More than 60% of patients can be
found in the two highest risk genotype combinations,
which were found in only 10.7% or controls. This
demonstrates that the used HLA typing procedure is
able to high extent predict T1D risk also in this diverse
population. Sensitivity and specificity of HLA-DR-DQ
based genotyping is in fact quite similar as described
in several European populations analysed by somewhat
varying genotyping schemes [15,29,30]. In spite of the
fact that in our study groups there were few Africans
and mulattos we think that it is representative of gen-
eral Brazilian population. The result of five centuries
of interethnic crosses of Europeans, Africans and au-
tochthonous Amerindians have created an extremely
heterogeneous population and studies of ancestry of
mitochondrial DNA in mostly white Brazilians showed
nearly equal amounts of Amerindian, African and Eu-
ropean matrilineal genetic contribution [31].
Somewhat more refined disease risk grading might
be possible also based on class II HLA typing, but larg-
er patient and control series should be typed for that
purpose. Genotyping for additional loci outside HLA
might also offer possibilities to increase the efficiency
of risk estimation. Insulin gene region and CTLA-4
gene are the two loci, which besides HLA can be listed
among confirmed loci although their total contribution
to diabetes risk, like also that of those remaining still to
be mapped, is small compared to HLA. Analysis of INS
gene −2221 C/T polymorphism confirmed the disese
association also in this population and the presence of
homozygous risk genotype might be included into the
risk estimation. OR associate with risk genotype is not
high but could further define especially those groups
with moderate HLA based diabetes risk. Another limit-
ing factor for the usage of INS gene analysis is the high
frequency of risk genotype among background popula-
tion. The used marker of CTLA-4 polymorphism could
not detect significant difference between patients and
controls and its efficiency in risk estimation must thus
be low.
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